Oral Bisphosphonate Related Osteonecrosis of the Jaw: A Challenging Adverse Effect
Author(s) -
İlke Coşkun Benlidayı,
Rengin Güzel
Publication year - 2013
Publication title -
isrn rheumatology
Language(s) - English
Resource type - Journals
eISSN - 2090-5475
pISSN - 2090-5467
DOI - 10.1155/2013/215034
Subject(s) - osteonecrosis of the jaw , medicine , bisphosphonate , osteoporosis , concomitant , adverse effect , bisphosphonate associated osteonecrosis of the jaw , dentistry
Oral bisphosphonates are the most commonly prescribed antiresorptive drugs for the treatment of osteoporosis. However, there are several adverse effects associated with oral bisphosphonates including the bisphosphonate related osteonecrosis of the jaw (BRONJ). With a better understanding of this side effect, reported incidences for BRONJ in oral bisphosphonate users have increased in time. The pathogenesis of BRONJ has not been well determined. Several risk factors such as dentoalveolar surgery, therapy duration, and concomitant steroid usage have been linked to BRONJ. Conservative and surgical methods can be preferred in the treatment. Preventative measures are of great importance for the patients at high risk. In this paper, osteonecrosis of the jaw secondary to oral bisphosphonates was reviewed in order to increase awareness as well as to renew the current knowledge.
Accelerating Research
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom
Address
John Eccles HouseRobert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom